Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of ...(cluding Pre-clinical Models) Presenta...),Health

Presentation Time: 5:30 PM - 7:30 PM

Location: Moscone Center, Hall A

Poster Board no.: I-115

MONDAY, DECEMBER 8th

Abstract 3691

TITLE: Phase I Results of Perifosine (KRX-0401) in Combination with

Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory

Multiple Myeloma (MM)

Session Name: Myeloma - Therapy, excluding Transplantation Poster III

Presentation Time: 5:30 PM - 7:30 PM

Location: Moscone Center, Hall A

Poster Board no.: III-773

Pre-Clinical Poster Presentations:

MONDAY, DECEMBER 8th

Abstract 3663

TITLE: Combination of Nab-Rapamycin and Perifosine Induces Synergistic

Cytotoxicity and Antitumor Activity Via Autophagy and Apoptosis in

Multiple Myeloma (MM)

Session Name: Myeloma - Pathophysiology / Preclinical Studies excluding

Therapy Poster III

Presentation Time: 5:30 PM - 7:30 PM

Location: Moscone Center, Hall A

Poster Board no.: III-745

Abstract 1555

TITLE: Phenotypic and Functional Effects of Novel Akt Inhibitor

Perifosine on Immune System

Session Name: Lymphocytes and Lymphocyte Activation Poster I

Presentation Time: 5:30 PM - 7:30 PM

Location: Moscone Center, Hall A

Poster Board no.: I-660

Copies of the above referenced abstracts can be viewed online through the ASH website, http://www.hematology.org.

KRX-0401 (Perifosine) Mechanism of Action and Profile

KRX-0401 (Perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of
'/>"/>